Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials.

Kinnunen, Kirsi M; Mullin, Ariana P; Pustina, Dorian; Turner, Emily C; Burton, Jackson; Gordon, Mark F; Scahill, Rachael I; Gantman, Emily C; Noble, Simon; Romero, Klaus; Georgiou-Karistianis, Nellie; Schwarz, Adam J

Kinnunen, Kirsi M; Mullin, Ariana P; Pustina, Dorian; Turner, Emily C; Burton, Jackson; Gordon, Mark F; Scahill, Rachael I; Gantman, Emily C; Noble, Simon; Romero, Klaus; Georgiou-Karistianis, Nellie; Schwarz, Adam J.

Afiliação

Kinnunen KM; IXICO, London, United Kingdom.
Mullin AP; Critical Path Institute, Tucson, AZ, United States.
Pustina D; Wave Life Sciences, Ltd., Cambridge, MA, United States.
Turner EC; CHDI Management/CHDI Foundation, Princeton, NJ, United States.
Burton J; Critical Path Institute, Tucson, AZ, United States.
Gordon MF; Critical Path Institute, Tucson, AZ, United States.
Scahill RI; Teva Pharmaceuticals, West Chester, PA, United States.
Gantman EC; Huntington's Disease Research Centre, UCL Institute of Neurology, London, United Kingdom.
Noble S; CHDI Management/CHDI Foundation, Princeton, NJ, United States.
Romero K; CHDI Management/CHDI Foundation, Princeton, NJ, United States.
Georgiou-Karistianis N; Critical Path Institute, Tucson, AZ, United States.
Schwarz AJ; School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.

Front Neurol ; 12: 712565, 2021.

Article em En | MEDLINE | ID: mdl-34744964

Palavras-chave

C-Path; Huntington's disease; biomarkers; clinical trials; neurodegenerative; volumetric MRI

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Observational_studies Idioma: En Revista: Front Neurol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google